Hyperthermia induced homologous recombination (HR) deficiency in cervical carcinoma

• Conditions: cervical cancer; 10013364; Cervical carcinoma

• Registration Number: NL-OMON40739
• Lead Sponsor: Verloskunde en Gynaecologie, subafdeling Gynaecologie en Gynaecologische Oncologie, Erasmus MC, Daniel den Hoed

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Last Update Posted: 23 April 2024

Recruitment & Eligibility

• Status: Pending
• Sex: Not specified
• Target Recruitment: 15

Inclusion Criteria

• Cervical cancer patients with a routine indication for primary treatment combined with hyperthermia
• Tumor lesions amendable for biopsies
• Age >18 years
• Platelets >100 x 10e9/L
• Written informed consent

Exclusion Criteria

• Current therapeutically use of anti-coagulant (coumarin, warfarin, heparin or low molecular weight heparin [LMWH]). LMWH if used for prophylaxis is allowed.
• Any psychological condition potentially hampering compliance with the study protocol.
• Patients who are treated in another institution for radiotherapy, with more than 2 hour travel distance.

Study & Design

• Study Type: Observational invasive
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
<p>The level of BRCA2 protein as detected by immuno (Western) blotting with<br /><br>anti-BRCA2 antibody before and after hyperthermia as a measure of homologous<br /><br>recombination (HR) deficiency. In parallel, part of the pre-hyperthermia<br /><br>obtained tumor cells will be incubated at 37*C or 41*C in the laboratory, as an<br /><br>ex vivo control experiment in the same patient.</p><br>

Secondary Outcome Measures

Name	Time	Method
<p>The presence of CTC before and after hyperthermia treatment. </p><br>